BioCentury | Dec 8, 2018
Product Development

Intermittent move beyond Blincyto

...leukemia (ALL) NA NR 32-42% (A) 7-15% 3-5% Continuous 28 days Intermittent Affimed N.V. (NASDAQ:AFMD) AFM13...
...of anti-CD20s from previous lines of therapy. Hitting the marks Roche’s mosunetuzumab and Affimed N.V.’s AFM13...
...rather than T cells by using the NK-cell marker Fcγ receptor IIIa (CD16a; FCGR3A; FcγRIIIa). AFM13...
BioCentury | Oct 12, 2018
Clinical News

Clinical holds for Affimed's T cell bispecific following patient death

...cells, AFM13, a bispecific human antibody targeting CD30 and Fcγ receptor IIIa (CD16a; FCGR3A; FcγRIIIa). AFM13...
...response; ALL: safety; pharmacodynamics, pharmacokinetics, immunological markers and efficacy Status: Phase I hold Milestone: NA Allison Johnson AFM11 AFM13 Affimed...
BioCentury | Oct 9, 2018
Clinical News

Affimed sinks after placing clinical hold on bispecific T cell engager

...cells, AFM13, a bispecific human antibody targeting CD30 and Fcγ receptor IIIa (CD16a; FCGR3A; FcγRIIIa). AFM13...
...and combination studies to treat blood cancers are expected at a medical conference this quarter. Allison Johnson AFM11 AFM13 Affimed...
BioCentury | Sep 28, 2018
Emerging Company Profile

Stopping chain swapping

...companies have multispecific antibodies in the clinic for cancer. The most advanced is Affimed N.V.’s AFM13...
BioCentury | Feb 9, 2018
Clinical News

Affimed reports Phase Ib/IIa data of AFM13 for cutaneous lymphoma

...the first dose cohort of a Phase Ib/IIa trial showing that once-weekly 1.5 mg/kg IV AFM13...
...of response and progression-free survival (PFS). The trial is sponsored by Columbia University Medical Center. AFM13...
...CD30 and Fc gamma receptor IIIa (CD16a; FCGR3A; FcgammaRIIa). Affimed N.V. (NASDAQ:AFMD), Heidelberg, Germany Product: AFM13...
BioCentury | Feb 9, 2018
Clinical News

Affimed reports Phase Ib data of AFM13 plus Keytruda for Hodgkin's lymphoma

...relapsed or refractory Hodgkin's lymphoma in a Phase Ib trial showing that 7 mg/kg IV AFM13...
...The open-label trial's primary endpoint is dose-limiting toxicities (DLTs). Secondary endpoints include safety and ORR. AFM13...
...CD30 and Fc gamma receptor IIIa (CD16a; FCGR3A; FcgammaRIIa). Affimed N.V. (NASDAQ:AFMD), Heidelberg, Germany Product: AFM13...
BioCentury | Jun 12, 2017
Company News

Celgene gets options to Dragonfly's NK receptor antibodies

...and Sanofi (Euronext:SAN; NYSE:SNY) are also developing NK cell receptor-based therapeutics. Affimed’s bispecific lead candidate, AFM13...
...NCR1 ; NKP46; CD335), FCGR3A , and undisclosed tumor antigens selected by Sanofi. Jaime De Leon AFM13 CAR-NKG2D CAR-T...
BioCentury | Mar 3, 2017
Emerging Company Profile

Dragonfly’s trinkets

...Fc gamma receptor IIIa ( FCGR3A ; FcgammaRIIIa ; CD16a) on NK cells. Lead candidate AFM13...
BioCentury | Feb 4, 2017
Emerging Company Profile

Bispecific simplicity

...highly potent molecules with good manufacturing yields. In a Phase I study of lead candidate AFM13...
BioCentury | Jan 26, 2017
Translation in Brief

NK cell double take

...other. When an NK cell engages the bispecific, it becomes activated. The platform’s lead product, AFM13...
...terms of the deal, MD Anderson will evaluate the combination of its NK cells and AFM13...
...declined to disclose timelines for preclinical results or entry to the clinic. - Lauren Martz Lauren Martz AFM13 Affimed...
Items per page:
1 - 10 of 27